EMS-Chemie Q3 sales dip 6%, guidance confirmed; China unit now fully owned

EMS-Chemie reported Q3 sales of CHF471 million, a 6% year-over-year decline and slightly below analyst expectations, though organic sales showed sequential improvement despite a challenging macroeconomic environment. The company maintained its full-year guidance, projecting sales below the prior year but EBIT slightly above, and announced the acquisition of the remaining 25% stake in its Chinese EFTEC unit for an estimated CHF160-210 million. Shares remained largely unchanged following the announcement.

Analysis

EMS-Chemie reported Q3 sales of CHF471 million, a 6% year-over-year decline and slightly below analyst expectations, yet organic sales showed sequential improvement, falling 2% compared to 4.8% in Q1 and 2.4% in Q2. This indicates some stabilization despite a challenging macroeconomic environment, supported by strong performance in Asia and market share gains in specialty products. The High Performance Polymers division's sales of CHF430 million were down 1.3% organically, largely meeting forecasts, while the Specialty Chemicals segment saw a significant 22% decline to CHF42 million, missing consensus by 9%.

The company announced the acquisition of the remaining 25% minority stake in its Chinese EFTEC unit, effective October 28, which will be financed from cash on hand. This unit is estimated to generate CHF150 million in annual revenue, with the transaction costing CHF160-210 million, representing 25-35% of EMS's projected 2025 free cash flow. This strategic move consolidates control over a significant revenue stream.

EMS maintained its full-year guidance, projecting sales below CHF2.07 billion (below previous year) but EBIT slightly above last year's CHF539 million, implying a 5-9% increase. This contrasts with consensus expectations of CHF1.95 billion sales (5.8% decline) and CHF551 million EBIT (2% increase), suggesting management anticipates stronger profitability than analysts. Shares remained largely unchanged following the announcement, reflecting a mixed market reaction to the sales miss and strategic acquisition.

Key Decisions for Investors

• Investors should monitor the integration of the EFTEC unit acquisition and its impact on future revenue and free cash flow generation, given the significant capital outlay.
• Evaluate the sustainability of the organic sales improvement and the company's ability to achieve its full-year EBIT guidance, particularly in light of the continued macroeconomic challenges and disparities between segment performances.
• Assess whether the strong performance in Asia and market share gains in specialty products can consistently offset weakness in other segments and the anticipated negative foreign exchange impacts.